Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Thomas Reiner
Sloan Kettering Inst Can Research, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Theragnostics, Ltd
Payment for services (e.g., consulting fees, honoraria, paid authorship)
Dr. Reiner serves on the Scientific Advisory Board for the company Theragnostics and is compensated for this service. Dr. Reiner is also a co-inventor on technology related to radiolabeled PARP inhibitor (PARP1) for imaging and radiotherapy; Theragnostics is licensing this technology from MSK. This research seeks to validate and expand on proof-of-principle radiotherapy data with 123I-PARPi, a small molecule Auger emitter targeted to the DNA repair enzyme PARP1. The aims of Theragnostics intersect with the aims of this research, and therefore, MSK has determined that a conflict of interest exists that needs to be managed.
Radioiodinated Multifunctional PARP1 Imaging Probes for Diagnosis and Therapy
Project Narrative This project seeks to develop targeted small molecules for a DNA repair enzyme, which will be labeled with a radiotherapeutic iodine isotope that emits Auger electrons, a form of radioactive decay that is confined to very small spaces. In preliminary experiments, we have shown that we can shuttle the therapeutic isotope extremely close to the DNA of glioblastoma cells, causing these cells to be killed, and, importantly, sparing the healthy surrounding tissues. We will use this agent as a single agent chemotherapy, but also in combination with external beam radiation, which will can help transport more Auger Electrons directly to the DNA, where they will inflict the greatest damage. 1
Filed on July 11, 2019.
Tell us what you know about Thomas Reiner's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Thomas Reiner filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Thomas Reiner | Sloan Kettering Inst Can Research | Conflict of Interest | Summit Biomedical Imaging, LLC | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.